Community Health Media

ILD Risk vs. Cardiotoxicity Avoided — How do the safety signals compare in DESTINY-Breast11? Drs. Mark Pegram and Neil Iyengar review ILD findings and the incidence of cardiac events, assessing the safety balance as it relates to administering an anthracycline-free curative regimen. 🔔 Subscribe for expert-level oncology updates and stream the complete episode on all podcast platforms. https://lnkd.in/eWm-bdNw #TDXd #DB11 #BreastCancer #HER2Positive #Oncology #ILD #Cardiotoxicity #ESMO2025

An 11% increase in pCR — but is it enough to predict long-term benefit? Drs. Pegram and Neil Iyengar explore whether DESTINY-Breast11’s results will translate into durable survival gains for HER2+ early-stage breast cancer. 👉 Watch more oncology conversations and listen to the full episode on your preferred streaming platform https://lnkd.in/eWm-bdNw #TDXd #BreastCancer #HER2Positive #DB11 #pCR #ESMO2025 #OncologyPodcast #CancerResearch

DESTINY-Breast11 delivers practice-changing data in the neoadjuvant setting. Can T-DXd replace anthracyclines for high-risk, HER2+ early-stage breast cancer? Drs. Pegram and Neil Iyengar break down trial design, endpoints, and clinical impact. 👉 Watch more expert insights and stream the full conversation now on all major podcast platforms https://lnkd.in/eWm-bdNw #BreastCancer #HER2Positive #TDXd #DB11 #ESMO2025 #Oncology #PrecisionOncology

Four cycles of T-DXd — could this open the door to adjuvant de-escalation? With higher pCR rates and reduced toxicity, DESTINY-Breast11 may redefine how we balance efficacy and treatment burden in HER2+ breast cancer. Hear from Neil Iyengar and Mark Pegram 🎧 Watch the full discussion and subscribe for more practice-changing insights in breast oncology. https://lnkd.in/eWm-bdNw #TDXd #DB11 #HER2Positive #BreastCancer #DeEscalation #Oncology #ESMO2025

TDXd for #Brain Metastases 🧠 Dr. rena callahan from from David Geffen School of Medicine at UCLA and Aditya Bardia from UCLA Health illustrate how TDXd has become the preferred treatment for #HER2-breast #cancer patients with brain #metastases, reshaping clinical practice standards. #tdxd #breastcancer

What happens when HER2-targeted therapies like T-DXd challenge not only clinical expectations, but also the very framework of breast cancer classifications? Drs. Paolo Tarantino and Jason A. Mouabbi explore how evolving HER2 definitions are reshaping patient care, trial design, and what we consider “treatable.” Their conversation dives into the complexities of HER2-low disease and why precision isn’t just about biomarkers—it’s about mindset. 🎥 Watch the full CHM Conversations episode for deeper insight into the shifting landscape of HER2+ breast cancer. #Oncology #BreastCancer #HER2Low #TDXd #CHMConversations #PrecisionMedicine